NAFDAC disowns PAX CVD PLUS for treatment of COVID-19

…As Prof Adeyeye says No remedy is yet registered or listed for COVID-19***

The NAFDAC Director-General, Prof Mojisola Christianah Adeyeye has debunked an advertorial claim by Pax Herbal Clinic and Research Laboratories, that the agency granted an endorsement for the use of its drug called PAX CVD PLUS for the treatment of COVID-19.

The Regulatory body in a disclaimer made available to the Maritime First described the notion as a hoax, stressing that neither PAX CVD PLUS nor any other drug is yet endorsed as an approved remedy for the treatment of COVID-19.

NAFDAC stated as below:

“The attention of the Agency has been drawn to an advertorial from Pax Herbal Clinic and Research Laboratories titled “AN OFFICIAL STATEMENT BY PAXHERBALS ON THE TREATMENT OF COVID-19”. The advertorial claims that Paxherbal has developed a new drug called PAX CVD PLUS for the treatment of COVID-19 and is working with NAFDAC to speed up approval for use of the drugs.

“The same advertorial claimed that the Director-General of NAFDAC has appointed experts to work with PAXHERBAL on what the company has described as a special project.

“The National Agency for Food and Drug Administration and Control (NAFDAC) wishes to inform the public that PAX CVD PLUS has not been registered nor listed for treatment of COVD-19, neither have we registered nor listed any other remedy for COVID-19.

Also read: NAFDAC: No vaccines would secure Nigeria’s usage approval, in next one year

“To set the records straight, at no time did the Director-General of NAFDAC, Prof Mojisola Christianah Adeyeye, or anyone in the Agency appoint any expert or staff to work with PAXHERBAL on any project.

“The company wrote a letter to NAFDAC informing the Agency about their development of an antiviral plant-based drug with potential to treat COVID-19 and an invitation to join their research team. The Agency politely declined since as a regulator of clinical trials, participation would be a conflict of interest. However, we encouraged them to carry out clinical trials that should be under strict supervision of the Agency to establish efficacy of their product. However, the clinical trial has not taken place.

“It is, therefore, unfortunate that PAXHERBALS have made claims that are not backed up by facts. This response is intended to correct the erroneous impression created by the advertorial”, the Director-General stated further.